TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.120nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.280nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.300nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.340nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.400nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.400nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.5nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.5nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 0.800nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
Affinity DataIC50: 0.900nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.10nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.20nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.40nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.5nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.5nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.5nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.80nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.80nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 1.90nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 2nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 2.20nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 2.30nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 2.40nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 2.70nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 2.70nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 2.70nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 3.20nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 3.5nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 3.90nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 4nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 4.40nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 4.60nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 5nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 6nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 6nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 6.10nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 7.5nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 8nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 10nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 11nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 11nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 13nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 13nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 14nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 16nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 17nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 21nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Allergan
US Patent
Allergan
US Patent
Affinity DataIC50: 23nMpH: 7.4 T: 2°CAssay Description:The PDE assay is based on the homogenous time-resolved fluorescence resonance energy transfer (TR-FRET) technology (LANCE® from Perkin Elmer). This c...More data for this Ligand-Target Pair